Signal stock

Why it jumped more than 11% today

  • Adaptive Biotechnologies Corp (NASDAQ:ADPT) stock price rose more than 11% in intraday trading today. That is why.

The stock price of Adaptive Biotechnologies Corp (NASDAQ:ADPT) – a commercial-stage biotech company that aims to translate adaptive immune system genetics into clinical products to diagnose and treat disease – rose more than 11%. % during intraday trading today. Investors respond positively to Adaptive Biotechnologies by announcing the launch of T-Detect Lyme.

This is the company’s second test to be made available through its growing T-Detect franchise. And the T-Detect test detects an immune response by taking advantage of the body’s unique T cell response to disease-associated antigens. T-Detect Lyme identifies T cells activated by Borrelia burgdorferi, the bacteria that causes Lyme disease, to help diagnose early-stage Lyme disease.

T-Detect Lyme – administered as a simple blood test – is intended to aid in the diagnosis of early Lyme disease in adult patients with signs and symptoms. And these symptoms include, but are not limited to, the presence of an erythema migrans (EM) rash, fever, chills, headache, fatigue, muscle and joint pain, and swollen lymph nodes.

In the United States, Lyme disease is the most common tick-borne disease with approximately half a million people newly infected per year. And early diagnosis of Lyme disease makes it easier to initiate treatment to halt disease progression. But today’s standard antibody tests can miss up to 75% of Lyme disease cases in the acute or early phase of infection.

In a clinical validation study in early-stage Lyme disease patients, the T-cell test was more accurate than major antibody tests. And T-Detect Lyme has a specificity of about 99% and showed more than 1.5 times greater sensitivity than standard bi-level tests (STTT) in patients who presented with a rash (54% vs 30% , respectively). In a separate study, T-Detect Lyme showed 3x greater sensitivity than STTT within the first four days of symptom onset (44% vs. 14%, respectively).

T-Detect Lyme is the latest app in Adaptive’s immune medicine platform, which uses Adaptive’s TCR sequencing capabilities and Microsoft’s cloud-scale AI to characterize the T cell repertoire and identify a clinical signal of the disease. And Adaptive is applying this approach to enable earlier and more accurate diagnosis of many infectious and autoimmune diseases. In early 2021, Adaptive Biotechnologies received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for the platform’s first diagnostic application, T-Detect COVID – which was used by over 30,000 patients to confirm SARS-CoV-2 infection.

KEY QUOTES:

“The T-Detect franchise harnesses the natural abilities of the immune system and the exquisite specificity of T cells to detect disease early. The availability of T-Detect Lyme may help shorten the time to an accurate diagnosis for patients with early-stage Lyme disease. Additionally, the addition of T-Detect Lyme will support the scaling up of clinical operations to enable our growing T-Detect portfolio, including testing in autoimmune diseases with high unmet need. T-Detect Lyme has demonstrated greater sensitivity than serology in early Lyme disease and can aid in the early diagnosis of up to twice as many cases that may be missed by traditional serology tests. We aim to further improve the sensitivity of the test over time by using new datasets from additional individuals to be able to help more patients.

— Sharon Benzeno, Ph.D., Business Manager, Immune Medicine, Adaptive Biotechnologies

“Lyme disease is a particularly heavy disease, and areas where Lyme disease is common are growing. Antibody development takes time; however, the majority of serological tests are requested in the early stages of infection, when susceptibility to STTT is lower. A T cell test can enhance existing options for patients and health care providers by measuring a different aspect of the immune response, the T cell, which may arise earlier than antibodies to help identify recent infections.

— Dr. Shari Rozen, Physician at Preferred Primary Care Physicians of Pittsburgh, and ImmuneSense Lyme Study Investigator

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.